The approval of COVID-19 vaccines in India this week were quicker than most had expected, but concerns over the approval process and pricing disagreements underscore some of the challenges that remain to widespread vaccination. On balance, we continue to assume that India’s most vulnerable will be largely vaccinated by Q2 2022. That would probably allow a rolling back of restrictions on most domestic activity during the second half of this year.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services